AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially lifethreatening infectious diseases.
Since November 2017, the first product from AiCuris is on the market. 
Letermovir, designed to inhibit the viral terminase of the human cytomegalovirus (CMV) and licensed to MSD, achieved market approval in the US, Europe and Japan for the prophylaxis of CMV infections in recipients of bone marrow transplants.
Further clinical programs include Pritelivir, a helicase-primase inhibitor, developed to treat recurrent labial herpes and genital herpes infections, AIC499, a resistancebreaking Gram(-) antibiotic and AIC649, an immune modulator targeted at Hepatitis B cure.
Overview:
| Field of Activity | Anti-infectives including antivirals (HCMV, HSV, Hepatitis B virus, Adenovirus) and antibacterials (hospital infections caused by multiresistant Gram-negative and Gram-positive bacteria). |
| Ownership Structure and Financing | Private investors, led by the family offi ce of the Dres. Strüngmann, former owners of Hexal. |
| Partners | Merck & Co. (MSD): Licensee of AiCuris’ HCMV drug Letermovir. AiCuris intends to move its projects to a clinical proof-of-concept and then to offer them for licensing/partnering. AiCuris is open for various types of collaborations and also pursues an active in-licensing strategy for early pre-clinical projects. |
| Products / Services | AiCuris’ Clinical Programs: Letermovir, HCMV, Registration (licensed to Merck&Co, MSD) AIC387 / AIC476, HCMV, Phase 1 Pritelivir, oral, HSV (genital herpes), Phase 2 Pritelivir, topical, HSV (labial herpes), Phase 2 AIC649, Hepatitis B Virus, Phase 1 AIC499, Gram-hospital infections, Phase 1 |
| Unique Selling Point | AiCuris’ innovative antibiotic and antiviral drugs act via new modes of action and are directed against new targets and/or represent novel chemical classes. Based on this, AiCuris‘ therapeutics are resistance-breaking by design. |
| Membership in networks / associations | BIO Deutschland, BioRiver, European Biopharmaceutical Enterprises (EBE), BEAM-Alliance |
| Date of Incorporation | 2006 |
| Number of Employees | 65 |
Contact person:
Dr. Holger Zimmermann
CEO
Contact:
| Telephone | +49 202 317 63 0 |
| Telefax | +49 202 317 63 11 77 |
| info@aicuris.com |
Address:
AiCuris Anti-infective Cures
Friedrich-Ebert-Str. 475 / Building 302
42117 Wuppertal
Website:
- AiCuris-Team für den Deutschen Zukunftspreis 2018 nominiert
- Nach FDA-Zulassung: AiCuris-Wirkstoff kommt nach Europa
- AiCuris' Lizenznehmer MSD erhält FDA-Zulassung für PREVYMIS (Letermovir)
- „Die Preisvorstellung von Antibiotika muss und wird sich ändern“
- AiCuris erhält Fast-Track-Status der FDA
- Dem Horror entgegen wirken
